NYSE:TDOC

Teladoc Inc (TDOC)

7.05
-0.26 (3.56%)
as of Jun 5, 2026, 8:00:00 pm Market Open.
131 watching
0
WATCH
Great run at start of pandemic. Difficulty is newer contracts are with health insurers, so margins are lower. Not as sticky a service as you might think. You can join, and then unjoin. Hasn't held up. Stock's a bit broken. Need to see price pattern improve and subscriber base more stable.
PAST TOP PICK
(A Top Pick Aug 26/20, Down 30%) Typical stay-at-home name. Growing pains. Last quarter had a wider loss than expected. Still sees 25% revenue growth per year. User base and revenue continue to grow. Valuation is a bit expensive. He's being patient, it's the way of the future.
HOLD
Price target is $166.85. Platform to get healthcare from a variety of professionals. Has grown revenue significantly, leader in the category of med-tech. Volatile. Yet to be profitable. A number of acquisitions. Still likes it.
DON'T BUY
The space is too crowded, too many companies with not enough demand.
BUY ON WEAKNESS
It's considered a stay-at-home pandemic play, so investors are avoiding it. He thinks TDOCE is better than that with upside. Let others sell it so you can pick it up cheap.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 01/20, Down 9.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with TDOC has triggered our stop at $175. To be disciplined, we recommend covering the balance of the position (along with the previous recommended gain of 27.5%). This creates an overall return on investment of 8.9%.
PARTIAL BUY
It's for real. He likes their game plan and recent acquisition. Problem is, they face more competition. If people think there'll be an economic book, TDC will underperform. Long term, this will be fine, though, because it was a great business model. Teledoc is part of the solution to save Medicare.
BUY

TDOC vs. WLL He likes the industry, especially during Covid. A lot of efficiency gains have been unlocked with telehealth platforms. He prefers TDOC in the US, especially after its recent integration.

BUY
Buy it. This is how people will get healthcare. Hospitals (in the U.S.) are too expensive.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Dec 01/20, Up 27.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with TDOC has achieved its $247 objective. To be disciplined, we recommend covering 50% of the position. We also recommend trailing up the stop to $175 (previously at $140).
BUY
Has done well because of stay at home. The way of the future. Virtual visits make a lot of sense. Revenue should continue to grow. Higher beta. Long-term secular growth play.
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly TDOC is a telemedicine provider. Five year sales growth has exceeded 60%. Revenue is expected to double this year and grow another 80% in 2021. Announcements recently of vaccines for COVID-19 has caused a brief pullback in share prices, making this a good time to enter. We would buy this with a stop-loss at $140, looking to achieve $247 -- over 25%. Yield 0% (Analysts’ price target is $247.20)
BUY
He expects people will stick with digital doctor consultations, post-Covid, because it's more convenient than an in-person visit. The deal to buy Luvongo was terrific merger, combining the leader of telemedicine with a digital health platform for people with chronic conditions like diabetes. However, the stock has fallen since that deal. Something has made investors nervous. However, recent good vaccine news has helped Teladoc though this was gaining acceptance even before Covid.
BUY
It has been a winner so far, despite some pullback recently. It is part of the thematic play that has been accelerated by covid. There are a lot of instances where it is more practical for the practitioner and the client to consult through telemedicine. Adoption will continue to rise over time.
BUY
They just did a fantastic merger wth Livongo. This will be the ultimate digital medical play.
Showing 16 to 30 of 37 entries